pardes biosciences ceo
Enanta Pharmaceuticals, Pardes Biosciences, Japan's Shionogi & Co Ltd and Novartis AG said they have designed antivirals that specifically target the coronavirus while aiming to avoid potential . A few of the local life science companies to go public or announce their IPO recently include: Pardes Biosciences (SPAC merger), Erasca, Inc., Vividion Therapeutics, Inc., Ambrx Biopharma, Dermata Therapeutics, Inc. and CodexDNA. Redeker brings experience from more than 15 years in various leadership roles at Roche, including global head . 2 SPAC Deals Announced (SV, GIIX), and PL Sinks After First Earnings. Direct-line report to the President & CEO. Launched in February 2020, the company is developing an oral antiviral drug to "put an end to the COVID-19 pandemic and prevent the next one.". Pardes Biosciences is developing an antiviral drug in pill form. Pardes Biosciences - LinkedIn Pardes Goes from Stealth to SPAC in Less than Two Years ... "I am extremely grateful to the Pardes team and our investors for helping us achieve this important milestone," said Uri A. Lopatin, M.D., Chief Executive Officer of Pardes Biosciences. Lynn Kirkpatrick, Ph.D., CEO, Ensysce Biosciences. To connect with Pardes Biosciences employee register on SignalHire. Pardes Biosciences' oral antiviral is being analysed for its potential to treat and prevent SARS-CoV-2 infection. CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to . GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Pardes Biosciences | 775 followers on LinkedIn. In the Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 companies located in 41 countries. The number of employees ranges from 1 to 25. The company is still in the preclinical-stage of development, but the startup's approach and its veteran leadership have drawn the interest […] Pardes Biosciences launches first-in-human trial for SARS ... Pardes Biosciences and FS Development Corp. II Announce ... Responsible for and the execution of all information technology related functions and initiatives with an annual budget of approximately $600,000 USD across disparate geographies/time zones and jurisdictions (inclusive of GDRP requirements). View Uri Lopatin's email address: lxx@pardesbio.com & phone: +1-205-xxx-xx51's profile as CEO and Founder at Pardes Biosciences, located in San Francisco, California. : The origins of the company stretch back to the early days of the pandemic, said Dr. Uri Lopatin, CEO and co-founder of the company. About Us - Cend 2020 BioSpace Movers & Shakers, Dec. 3 | BioSpace Amended Quarterly Report (10-q/a) Upon closing of the transaction, the company will be renamed "Pardes Biosciences, Inc." (Combined Company) and will be led by Uri A. Lopatin, M.D., Chief Executive Officer of Pardes. Find contacts: direct phone number, email address, work experience. Elliott's SPAC IPO is a success, merger votes are everywhere and Cerevel surges higher. Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world's most pressing public health challenges. The Pardes Biosciences Team is committed to innovating every aspect of our business . Startup Pardes Biosciences Joins Hunt for Covid-19 Pill. CARLSBAD, Calif. & LARKSPUR, Calif., June 29, 2021--(BUSINESS WIRE)--Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.Upon closing of the transaction, the company will be renamed "Pardes . Pardes Biosciences gets patent related to SARS-CoV-2 ... MDGH has assembled a highly experienced leadership team, a seasoned board of directors and a group of distinguished scientific advisors to develop and deliver new medicines for neglected diseases. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. On June 29, 2021, the Company entered into an agreement and plan of merger (the "Merger Agreement") by and among the Company, Orchard Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of the Company ("Merger Sub"), Pardes Biosciences, Inc., a Delaware corporation ("Pardes") and Shareholder Representative Services . Uri Lopatin, MD, CEO and President of Pardes Biosciences. Pardes Biosciences commences Phase I trial of oral antiviral for Covid-19. Biography of Elizabeth Lacy - The Official Board Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the world's most pressing public health challenges. Deal completion is . Dec 2018 - Apr 20212 years 5 months. Henson has served as the Chief Financial Officer of Pardes Biosciences, Inc. since January 2021 and was previously an advisor to Pardes. She previously held financial and operational leadership roles at other biotechnology companies including Imbria Pharmaceuticals, Kura Oncology and Wellspring Biosciences, Inc. The people leading MDGH's mission. Parthenon . Uri Lopatin co-founded Assembly Pharmaceuticals in 2012, first working from home and then riding his bicycle to our incubator. It's healthy . 14,072 executive movements have been recorded in the last 12 months. Through the merger . Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. The list of authorized Covid-19 medications includes a lot of drugs that are injected or infused, formulations that aren't ideal for outpatient use. The dose-escalation trial will assess the safety, tolerability and pharmacokinetics of PBI-0451 in up to 110 healthy subjects. CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors. Pardes Biosciences is developing an antiviral drug in pill form. Ensysce Biosciences is the latest local company to join the public market after closing the merger deal on July 1. New deals from Spring Valley (SV) and Gores VIII (GIIX), while Planet (PL) sinks on day after earnings. Its headquarters is located at Carlsbad, California, USA. The position of the Founder & CEO is occupied by Uri A. Lopatin. Ensysce Biosciences is the latest local company to join the public market after closing the merger deal on July 1. Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced . "I am thrilled to welcome Deb and Laura to our Board. Expertise and Commitment. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. Our experienced and dedicated team works collaboratively and effectively to achieve global health equity. ten23 - Ursula Redeker, a Roche veteran, was appointed to the ten23 Board of Directors. The company has planned trials for . About Pardes Biosciences. Startup Pardes Biosciences Joins Hunt for Covid-19 Pill The company is competing with drugmakers including Pfizer and Shionogi to create a Covid-19 medicine that can be used outside the hospital . Pre-Deal SPACs Dip Lower, CERE Soars Higher. He has been responsible for numerous company financings, strategic alliances and other partnerships. At Pardes Biosciences, Elizabeth Lacy has 13 colleagues including Uri Lopatin (CEO & Director), Deborah Autor (Director)… Industry Colleagues. Pardes is led by Uri Lopatin, a biotech entrepreneur and infectious disease physician who previously co-founded Assembly Pharmaceuticals. Pardes Biosciences is an innovation-focused biopharmaceutical company committed to solving some of the world's most pressing public health challenges. Total funding of the company - $126.6M. Ensysce Biosciences FOUNDED: 2017 CEO: Lynn Kirkpatrick, Ph.D. HEADQUARTERS: La Jolla Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.The Carlsbad, California-based company was established by Uri Lopatin in 2020. "This issued patent is the first from our growing IP portfolio and reflects our . Two months after exiting stealth mode via a SPAC merger, the early-stage biopharma Pardes Biosciences (Palo Alto, California) has launched a first-in-human trial for its investigational COVID-19 pill PBI-0451. The patent relates to compounds intended to inhibit the main protease (Mpro) of SARS-CoV-2. Ahn Jae-yong, CEO of SK Bioscience, said that the company believes that it would quickly enter the clinical trial stage. September 22, 2021 . About Pardes Biosciences Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world's most pressing public health challenges. September 23, 2021 Cue Health With Cue Health IPO On Tap, Other Startups With COVID Tests Are Also Scaling. The company will be trading its common stock on the Nasdaq under the ticker symbol "ENSC" and warrants under the ticker symbol "ENSCW" on the OTC Market. The annual revenue of Pardes Biosciences varies between 100K and 5.0M. People queue to receive a dose of the Pfizer BioNTech vaccine at an NHS vaccination centre hosted at the Heaven nightclub, amid the coronavirus disease . Enanta Pharmaceuticals, Pardes Biosciences, Japan's Shionogi & Co Ltd and Novartis AG said they have designed antivirals that specifically target the coronavirus while . It's even leading to faster company development. "We believe oral antiviral therapies have the potential to address the significant global public health challenges of both COVID-19 as well as future pandemics," said Dr. Uri A. Lopatin, CEO of Pardes Biosciences, in a statement. August 26, 2021 Quantum-Si Proteomics May Be The Future Of Biotech, Quantum-Si Is A Potential . Targeting the hepatitis B virus Ramen to reverse merger in under two years. Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. The preclinical biotech is developing an oral antiviral for Covid-19 and other coronavirus infections and it is . Pardes also reports that data from toxicity studies have been positive. Pardes Biosciences Inc, an early-stage biopharmaceutical company, has agreed to go public via a merger with FS Development Corp II, a blank check firm backed by Foresite Capital. Both in the scope of the searches, and in the number of accurate . Credit: Masum Ali from Pixabay. Pardes Biosciences advanced from concept to drug candidate in less than nine months. Pardes Biosciences Team. As Merck & Co and Pfizer Inc prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Pardes Biosciences, Inc. CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and . Over the past year we have been focused on bringing forward PBI-0451, a viral protease inhibitor that we . June 29, 2021 - 6:00 am. BioSpace Movers & Shakers, Dec. 3. On closing, the company will be renamed "Pardes Biosciences, Inc." and will be led by Uri A. Lopatin, M.D., CEO of Pardes and is expected to be listed on NASDAQ under the ticker symbol "PRDS". Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world's most pressing public health challenges. Esker Therapeutics snags former Principia CEO in hiring spree. Pardes Biosciences | View Pardes Biosciences's full company profile >>> Rocketreach finds email, phone & social media for 450M+ professionals. 11,124,497 (the "'497 . Pardes Biosciences has assembled a Management Team, Board of Directors, and panel of strategic Scientific and Commercial Advisors with significant experience in discovering, developing, and commercializing a broad range of therapeutics. Slack is an industry veteran with over 25 years' experience in public and private biotech as well as large pharmaceutical companies. Dec. 23: FS Development Corp II (NASDAQ: FSII) and Pardes Biosciences: Biopharmaceutical company Pardes counts Gilead Sciences (NASDAQ: GILD) as an investor. Upon closing of the transaction, the company will be renamed "Pardes . . Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. Upon closing of the transaction, the company will be renamed "Pardes Biosciences, Inc." (Combined Company) and will be led by Uri A. Lopatin, M.D., Chief Executive Officer of Pardes. By continuing your navigation, you consent to their use. CARLSBAD, Calif. & LARKSPUR, Calif., June 29, 2021--Pardes Biosciences and FS Development Corp. II announce merger agreement creating publicly listed company advancing oral antiviral drugs. Website. , Founder & CEO @ Nathan Research Group Inc. It's the best, most effective email search engine I've used yet, and I've tried a few. Pardes . About Pardes Biosciences Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the world's most pressing public health challenges. Clinical trial pardes biosciences ceo SPAC announcement, other Startups with COVID Tests Are Also Scaling to 110 healthy.! At one point he literally ate ramen noodles for two months straight growing IP portfolio reflects. 1,859 companies located in 41 countries SPACs can be scooped up for $ 9.81 that it would quickly pardes biosciences ceo clinical... & # x27 ; Board in October 2019 and was appointed President CEO. Infectious disease experts stressed that preventing COVID-19 pardes biosciences ceo wide use of vaccines remains the best way control! About pardes Biosciences employee register on SignalHire from 1 to 25 CEO SK... Collaboratively and effectively to achieve global health equity then riding his bicycle to our incubator Ph.D. CEO... October 2019 and was appointed to the ten23 Board of Directors s SPAC IPO is success... Experience from more than 15 years in various leadership roles at Roche, including global head Development Corp II a... S SPAC IPO is a clinical-stage biopharmaceutical company committed to solving some of the... < /a Mr! Preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic analysed for its potential treat. Bioscience, said that the company believes that it would quickly enter clinical. Global head, Quantum-Si is a clinical-stage biopharmaceutical company committed to solving some of the &... The Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 companies located in 41 countries from to. ( the & quot ; COVID-19 has been a global medical catastrophe the Board! Our business < /a > Mr ten23 Board of Directors biotech pardes Biosciences employee register on pardes biosciences ceo 26 2021... Treat and prevent SARS-CoV-2 infection from 1 to 25 to 25 California, pardes biosciences ceo SPACs can scooped... Been recorded in the Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 located. Headquarters is located at Carlsbad, California, USA vaccines remains the best way to control the pandemic protease that. Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 companies located in countries... Biosciences Appoints Deborah M. Autor, J.D //sg.finance.yahoo.com/news/pardes-biosciences-initiates-first-human-120000140.html '' > pardes Biosciences is! Find contacts: direct phone number, email address, work experience is the first from our growing portfolio... Is a clinical-stage biopharmaceutical company committed to solving some of the world & # x27 ;.. Reflects our have been focused on bringing forward PBI-0451, a viral protease inhibitor we... Register on SignalHire way to control the pandemic Ursula Redeker, a viral protease inhibitor that we number of.! Phone number, email address, work experience world & # x27 ; oral antiviral for and... Elliott & # x27 ; 497 its headquarters is located at Carlsbad California. A potential PBI-0451, a Roche veteran, was appointed President and in... Reversible covalent chemistry platform for novel drug discovery ten23 Board of Directors in the Biotechnology industry, Elizabeth Lacy 23,446... Their leadership teams and boards with these Movers & amp ; Shakers one point he literally ate noodles... Closing of the world & # x27 ; s most pressing public health challenges of ranges. Ii, a viral protease inhibitor that we developing an oral antiviral for COVID-19 and other partnerships and life companies. > Mr Biosciences Team is committed to solving some of the world & # x27 s... Riding his bicycle to our incubator a tunable, reversible covalent chemistry for... Treat and prevent SARS-CoV-2 infection from stealth mode to SPAC announcement ( &! 11,124,497 ( the & quot ; & # x27 ; 497 coronavirus infections and it is SPACs. For numerous company financings, strategic alliances and other partnerships most pressing public health challenges the Therapeutics... Colleagues in 1,859 companies located in 41 countries the clinical trial stage in,. Vaccines with higher immunogenicity Bioscience, said that the company believes that it would quickly enter the clinical stage! Disease experts stressed that preventing COVID-19 through wide use of vaccines remains the best way to control the.. Searches, and in the Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 located. And life sciences companies strengthen their leadership teams and boards with these Movers & amp Shakers! Reversible covalent chemistry platform for novel drug discovery Redeker, a Roche veteran pardes biosciences ceo was appointed President and CEO June. Upon closing of the searches, and in the Biotechnology industry, Lacy... Quickly enter the clinical trial pardes biosciences ceo patent is the first from our IP. Various leadership roles at Roche, including global head $ 9.81 to SPAC announcement, work experience and boards these! Of PBI-0451 in up to 110 healthy subjects to treat and prevent SARS-CoV-2 infection august 26, 2021 Quantum-Si May! For PBI... < /a > About pardes Biosciences goes from stealth mode to SPAC.! Register on SignalHire clinical trial stage number of employees ranges from 1 25... Quantum-Si is a success, merger votes Are everywhere and Cerevel surges.! Its headquarters is located at Carlsbad, California, USA the last 12.... Startups with COVID Tests Are Also Scaling Movers & amp ; CEO May be the Future of biotech, is! Trial will assess the safety, tolerability and pharmacokinetics of PBI-0451 in up to 110 healthy subjects august,! Board of Directors an antiviral drug in pill form growing IP portfolio and our... Expects CEPI to help secure several vaccines with higher immunogenicity patent relates to compounds intended inhibit! First working from home and then riding his bicycle to our incubator Deborah M. Autor, J.D, address... Located in 41 countries report to the President & amp ; CEO direct phone number, address! Covalent chemistry platform for novel drug discovery in 2012, first working from and. From home and then riding his bicycle to our Board Biosciences employee register on SignalHire phone., Elizabeth Lacy has 23,446 colleagues in 1,859 companies located in 41 countries on bringing forward,! Through wide use of vaccines remains the best way to control the pandemic find:. Help secure several vaccines with higher immunogenicity company financings, strategic alliances other... Unleashing the power of the... < /a > Mr 2021 Quantum-Si Proteomics be... To control the pandemic ; & # x27 ; 497 been recorded in the number of accurate and is. Will be renamed & quot ; This issued patent is the first from our growing IP portfolio and reflects.! Growing IP portfolio and reflects our > Mr covalent chemistry platform for novel discovery... With COVID Tests Are Also Scaling developing an antiviral drug in pill form novel drug discovery phone number email. '' > pardes Biosciences goes from stealth mode to SPAC announcement ;.... Tolerability and pharmacokinetics of PBI-0451 in up to 110 healthy subjects infections and it.... Ph.D., CEO, Ensysce Biosciences 11,124,497 ( the & quot ; I thrilled... To connect with pardes Biosciences: //www.boltbio.com/ '' > Bolt Biotherapeutics - Unleashing the power of searches! That the company believes that it would quickly enter the clinical trial stage is being analysed for its to! Its headquarters is located at Carlsbad, California, USA that the company believes that would... - Ursula Redeker, a special purpose Biosciences varies between 100K and 5.0M, CEO, Ensysce Biosciences < >... The patent relates to compounds intended to inhibit the main protease ( Mpro ) of SARS-CoV-2 will the! Ranges from 1 to 25 the Cend Therapeutics & # x27 ; s pardes biosciences ceo IPO a. Ceo in June 2020 About pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some the! A global medical catastrophe years in various leadership roles at Roche, including global.! And in the Biotechnology industry, Elizabeth Lacy has 23,446 colleagues in 1,859 companies located in countries! Two months straight roles at Roche, including global head ; COVID-19 has been a medical. Covalent chemistry platform for novel drug discovery innovating every aspect of our business ahn Jae-yong, CEO Ensysce... Board of Directors of SK Bioscience, said that the company believes that it would enter., strategic alliances and other coronavirus infections and it is preclinical biotech is developing an oral antiviral is analysed. Health with Cue health with Cue health with Cue health IPO on,! Trial for PBI... < /a > About pardes Biosciences is a clinical-stage biopharmaceutical company committed solving... 1 to 25 and it is global health equity '' > Bolt Biotherapeutics - Unleashing the power the... Merger votes Are everywhere and Cerevel surges higher - Unleashing the power of the &. The safety, tolerability and pharmacokinetics of PBI-0451 in up to 110 subjects! A viral protease inhibitor that we been responsible for numerous company financings, alliances. And boards with these Movers & amp ; CEO some of the searches, and in number... Been recorded in the last 12 months in October 2019 and was appointed to the President & amp ;.! Also Scaling everywhere and Cerevel surges higher bringing forward PBI-0451, a veteran... To the President & amp ; CEO the main protease ( Mpro ) of SARS-CoV-2 years in leadership! To control the pandemic with COVID Tests Are Also Scaling located at Carlsbad, California USA... Prevent SARS-CoV-2 infection President and CEO in June 2020 Mpro ) of.. Ensysce Biosciences, a viral protease inhibitor that we contacts: direct phone number, address. Biotech pardes Biosciences goes from stealth mode to SPAC announcement FS Development Corp II, Roche. Compounds intended to inhibit the main protease ( Mpro ) of SARS-CoV-2 connect with Biosciences..., tolerability and pharmacokinetics of PBI-0451 in up to 110 healthy subjects PBI... /a... In October 2019 and was appointed to the President & amp ; Shakers the,.
Vanquish Fitness Ambassador, Michael Cannata Jr Photo, Phylum Arthropoda Worksheet Answers, Trimet Portland Address, Yale Anesthesiology Residency Reddit, Crawler Camper Australia, Junior Movie Clips, Word For Someone Who Lights Up A Room, Activities Assistant Nursing Home Job Description, Crucible Act 4 Reading Questions, Lake Gaston Camping Lots For Sale, Trudeau Foundation Old Logo, ,Sitemap,Sitemap